IgG Antibodies to GlcNAc<i>β</i> and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment

<div>Comparison of anti-glycan IgG levels (mean values) in patients with stages F0 (dark columns) and F1–4 (light columns). The bars indicate the standard deviation (upper SD). The dilution of sera 1 : 50.</div>

Disease Markers

fig1

Figure 1

Figure 1: IgG Antibodies to GlcNAc<i>β</i> and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment 

Figure 1 | IgG Antibodies to GlcNAcβ and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment 